Clinical Roundup

Takeda Pharmaceutical Co. Ltd. announced the randomized, phase III TOURMALINE-MM3 study met its primary endpoint, demonstrating single-agent oral Ninlaro (ixazomib) as a maintenance therapy resulted in a statistically significant improvement in progression-free survival versus placebo.

A study by researchers from the International Agency for Research on Cancer, published in JAMA Oncology, demonstrates that a blood test measuring four protein biomarkers can improve the identification of individuals who would later develop lung cancer.

Genentech, a member of the Roche Group, announced that phase III IMpassion130 study met its co-primary endpoint of progression free survival.

According to data presented by NewLink, all 10 newly diagnosed DIPG patients in a phase I study demonstrated initial symptomatic improvement after treatment with indoximod and chemotherapy.

AstraZeneca and Merck announced positive results from the randomized, double-blind, placebo-controlled, phase III SOLO-1 trial of Lynparza (olaparib) tablets.

Genentech said that the phase III IMpower133 study met its co-primary endpoints of overall survival and progression-free survival at its first interim analysis.

Taiho Oncology Inc. and Servier announced clinical data from the pivotal phase III trial (TAGS) evaluating LONSURF (trifluridine and tipiracil, TAS-102) plus best supportive care (BSC) versus placebo plus BSC in patients with previously treated metastatic gastric cancer refractory to standard therapies.

To ensure the well-being and safety of healthcare providers and patients, the Oncology Nursing Society developed the Toolkit for Safe Handling of Hazardous Drugs for Nurses in Oncology.